Loyola University of Chicago has made significant contributions to the Southwest Oncology Group(SWOG) during the current grant cycle by accruing large numbers of patients, with submission of high quality data, and by making significant scientific contributions to SWOG. Loyola has continued to maintain excellent accrual in spite of the threats to clinical research from managed care. During the last year they had 143 registrations with 106 (74 percent) coming from the member institution; 55 percent of those patients were female and 15 percent were minorities. Ninety-eight percent of those cases were considered evaluable. Five faculty members have served as Chairs or Co-Chairs of committees or subcommittees. Thirty-eight faculty members actively participated in one or more committees. Seventeen faculty members have served as principal or co-coordinators of over 73 protocols. Twenty-three of these protocols were based on pilot studies conducted by Loyola investigators. Twelve faculty members have made significant contributions to SWOG core services. Eleven faculty members have published over 63 SWOG papers and 53 abstracts. The multi-disciplinary nature of Loyola's participation is evidenced by the fact that hematologists/oncologists, surgeons, radiotherapists, and pathologists have each made scientific contributions to SWOG. Multi-disciplinary interactions are also fostered by the movement of faculty clinics and offices to the newly opened Cardinal Bernardin Cancer Center. In addition. the Cancer Center will replace Hematology/Oncology as the organization responsible for this grant and data management will become a Cancer Center core service. In the latest SWOG evaluation of Loyola, this institution ranked in the top quartile of all members in the following categories: patient registration, committee membership, study coordination, and authorship. In addition, the Loyola SWOG grant has always been viewed as having a low cost per case and the grant has never had a Type V funding reduction. As outlined in the CCIRC guidelines, support is requested to permit continuation of Loyola's scientific leadership and patient accrual during the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046282-16
Application #
6626576
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1988-01-01
Project End
2004-03-31
Budget Start
2003-02-21
Budget End
2004-03-31
Support Year
16
Fiscal Year
2003
Total Cost
$402,352
Indirect Cost
Name
Loyola University Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Statler, Abby; Othus, Megan; Erba, Harry P et al. (2018) Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood 131:2782-2788
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Stiff, Patrick J; Montesinos, Pau; Peled, Tony et al. (2018) Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biol Blood Marrow Transplant 24:1463-1470
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585

Showing the most recent 10 out of 238 publications